Stork Club Fertility Outcomes Exceed National Benchmarks With Independent Validation
18 Mar 2024
Stork Club outperforms across industry-standard key measures for more and healthier births and babies born via IVF, setting new standards in reproductive care.
SAN FRANCISCO, March 18, 2024 /PRNewswire/ -- Stork Club, a pioneering enterprise reproductive care benefits solution, announced today that it outperforms national averages on all key performance measures. This leads to significantly fewer IVF cycles, and healthier pregnancies, births, and babies born via IVF compared with the US average. These results, validated by an independent auditor, come after Stork Club launched Performance Guarantees for 100% cost accountability tied to the clinical and financial outcomes provided to employers.
Stork Club engaged Milliman, Inc., an independent global leader in actuarial services, to evaluate its approach for comparing its results against national benchmarks. In its evaluation, Milliman actuaries concluded that Stork Club's methodology is appropriate and reasonable for estimating clinical performance differences between the national population and individuals who received care under Stork Club's coverage across six key performance metrics.
Stork Club's most recently published outcomes are the following:
Preview
Source: PRNewswire
Stork Club Fertility Care vs National Outcomes (USA)
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.